Lucentis

Lucentis is an FDA approved injectable medication that block the effects of Vascular Endothelial Growth Factor, (VEGF). VEGF is implicated in the development and progression of wet macular degeneration, diabetic retinopathy, and macular edema. VEGF not only promotes the growth of new abnormal blood vessels but increases the permeability of existing vessels leading to leakage. By blocking VEGF, Lucentis can, in some cases, improve outcomes in patients with a broad variety of retinal and macular diseases. Currently, Lucentis is FDA approved and covered by Medicare and most insurance companies for the treatment of wet macular degeneration. The physicians at Retina Group of Florida have extensive experience with the use of Lucentis, having participated in the clinical trials of Lucentis prior to its FDA approval